Wild-type p53, a tumour suppressor, has been reported to downregulate PIK3CA expression in ovarian cancer. Molecular profiling of HGSOC showed alterations in pro-survival, PI3K/AKT pathways genes in 34% of cases along with an overwhelming presence of p53 mutations (>96%). My work involves studying the association of oncogenic mutant p53 with the PIK3CA/AKT signalling pathway in HGSOC and test the efficacy of PIK3CA inhibitors on cells expressing mutant p53 as well as on patient derived primary cells.
